



PAN MERSEY AREA PRESCRIBING COMMITTEE
PRESCRIBING POLICY STATEMENT
REF: PS209 FINAL
APC BOARD DATE: 25 APR 2018
PENDING CCG APPROVAL



Pan Mersey
Area Prescribing Committee

BRODALUMAB solution for injection (Kyntheum[®] ▼)

RED

The Pan Mersey Area Prescribing Committee recommends the prescribing of BRODALUMAB solution for injection (Kyntheum[®] ▼), by specialists only, for treating plaque psoriasis in accordance with NICE TA511.

NICE technology appraisal (TA) 511¹ [21 March 2018] recommends brodalumab as an option for treating plaque psoriasis in adults only if:

- > the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 **and**
- > the disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated **and**
- > the company provides the drug with the discount agreed in the patient access scheme.

Stop brodalumab at 12 weeks if the psoriasis has not responded adequately, defined as:

- > a 75% reduction in the PASI score (PASI 75) from when treatment started **OR**
- > a 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from when treatment started.

Prescribing and monitoring of therapy must be retained by a specialist in the management of plaque psoriasis.

The accompanying NICE costing template for this TA estimates that the use of brodalumab will be cost neutral once the PAS discount is applied. Brodalumab is an option alongside current standard treatment options and practice is not expected to change substantially as a result of this guidance.

This recommendation is not intended to affect treatment with brodalumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Reference:

1. National Institute for Health and Care Excellence. Technology Appraisal Guidance (TA) 511: Brodalumab for treating moderate to severe plaque psoriasis, 21 March 2018. Accessed 21 March 2018 at: <https://www.nice.org.uk/guidance/ta511>
National Institute for Health and Care Excellence. Resource Impact template: Brodalumab for treating moderate to severe plaque psoriasis (TA511), March 2018. Accessed 05 April 2018 at: <https://www.nice.org.uk/guidance/ta511/resources>

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.